Cardiff Protides Investment

RNS Number:9265E
Biofusion PLC
02 October 2007


For immediate release                                            2 October 2007


                                 BIOFUSION PLC
                         ("Biofusion" or "the Company")

                 BIOFUSION INCREASES STAKE IN CARDIFF PROTIDES
                 

Biofusion plc (AIM: BFN), the university IP commercialisation company that turns
world class research into business, is today pleased to announce that it has
invested #200,000 into Cardiff Protides Limited ("Cardiff Protides"), a drug
delivery spin-out company, raising its holding to 50% of the company.

Previously, Biofusion held a 22.5% stake in Cardiff Protides through its
agreement with Cardiff University. The funding provided by Biofusion will allow
Cardiff Protides to continue to develop improved versions of known
nucleoside-based anti-cancer drugs which have the potential to dramatically
increase the ability of the drug to enter their target cells in the body.

Cardiff Protides' technology is based on research conducted by Professor
Christopher McGuigan at Cardiff University.

For further information about Biofusion or Cardiff Protides please contact:

Biofusion                                                    [phone]
David Baynes, CEO

Cardiff Protides                                                [phone]
Jon Dickens

Buchanan Communications                                      [phone]                                        
Lisa Baderoon / Mary-Jane Johnson / Catherine Breen

Nomura Code                                                  [phone]
Phil Walker / Clare Terlouw


About Biofusion

Biofusion was established in 2002 to commercialise university-generated IP.
Biofusion has signed long term agreements with two of the UK's top ten research
intensive universities (University of Sheffield and Cardiff University) giving a
combined R&D spend attributable to Biofusion of approximately #114 million a
year. The Company has a portfolio of over 20 spin-out companies.

Biofusion's first agreement was a ten-year exclusive arrangement with the
University of Sheffield for the commercialisation of IP owned by the University
in the area of medical life sciences. Biofusion has shareholdings in a portfolio
of Sheffield University spin-out companies including Asterion, Axordia,
Celltran, Lifestyle Choices, Diurnal and Phase Focus. The University of
Sheffield was ranked 5th in the UK for the quality of its life sciences research
and will be spending an estimated #0.5bn of research funding over the lifetime
over the life of the Sheffield Agreement.

In January 2007, Biofusion completed a long-term exclusive agreement with
Cardiff University, to commercialise 100% of all Cardiff University's
research-generated IP. Biofusion has shareholdings in a portfolio of Cardiff
University spin-out companies including Abcellute and Q-Chip. Cardiff University
was ranked 7th in the UK in the most recent research rankings and will be
spending over #1.0bn of research funding over the lifetime over the life of the
Cardiff Agreement.

www.biofusion.co.uk


About Cardiff Protides

Cardiff Protide's technology is based on Professor Christopher McGuigan's
research which enables the discovery of new and improved nucleoside based drugs.
This approach has been successfully utilised with a number of major
pharmaceutical companies in the anti-viral field and has more recently been
applied in the anti-cancer field. Cardiff Protide's vision is to become a
leading developer of cutting edge nucleoside based pharmaceuticals targeted at
areas of unmet medical need, initially for the treatment of cancer.






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCMBBPTMMBMBAR